NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition
2026-04-21 19:31:26 ET
More on NEXGEL
- NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript
- Quant snapshot: Delta Air Lines leads top-rated names as Byrna Technologies, Simulations Plus lag
- Seeking Alpha’s Quant Rating on NEXGEL
- Historical earnings data for NEXGEL
- Financial information for NEXGEL
Read the full article on Seeking Alpha
For further details see:
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisitionNASDAQ: NXGL
NXGL Trading
14.42% G/L:
$0.595 Last:
377,697 Volume:
$0.53 Open:










